April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
EFFICACY OF AFLIBERCEPT IN JAPANESE PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY INSENSITIVE TO RANIBIZUMAB TREATMENT
Author Affiliations & Notes
  • Toshiaki Hirakata
    Ophtalmology, National Hospital Organization, Tokyo Medica Center, Meguro-ku, Japan
    Laboratory of Visual Physiology, National Institute of Sensory Organs, National Tokyo Medical Center, Meguro-ku, Japan
  • Yuko Nishikawa
    Ophtalmology, National Hospital Organization, Tokyo Medica Center, Meguro-ku, Japan
    Laboratory of Visual Physiology, National Institute of Sensory Organs, National Tokyo Medical Center, Meguro-ku, Japan
  • Kaoru Fujinami
    Laboratory of Visual Physiology, National Institute of Sensory Organs, National Tokyo Medical Center, Meguro-ku, Japan
    Ophthalmology, Keio University, School of Medicine, Shinjyuku-ku, Japan
  • Ken Watanabe
    Ophtalmology, National Hospital Organization, Tokyo Medica Center, Meguro-ku, Japan
    Laboratory of Visual Physiology, National Institute of Sensory Organs, National Tokyo Medical Center, Meguro-ku, Japan
  • Kazushige Tsunoda
    Ophtalmology, National Hospital Organization, Tokyo Medica Center, Meguro-ku, Japan
    Laboratory of Visual Physiology, National Institute of Sensory Organs, National Tokyo Medical Center, Meguro-ku, Japan
  • Toru Noda
    Ophtalmology, National Hospital Organization, Tokyo Medica Center, Meguro-ku, Japan
    Laboratory of Visual Physiology, National Institute of Sensory Organs, National Tokyo Medical Center, Meguro-ku, Japan
  • Kunihiko Akiyama
    Ophtalmology, National Hospital Organization, Tokyo Medica Center, Meguro-ku, Japan
    Laboratory of Visual Physiology, National Institute of Sensory Organs, National Tokyo Medical Center, Meguro-ku, Japan
  • Footnotes
    Commercial Relationships Toshiaki Hirakata, None; Yuko Nishikawa, None; Kaoru Fujinami, None; Ken Watanabe, None; Kazushige Tsunoda, None; Toru Noda, None; Kunihiko Akiyama, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3836. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Toshiaki Hirakata, Yuko Nishikawa, Kaoru Fujinami, Ken Watanabe, Kazushige Tsunoda, Toru Noda, Kunihiko Akiyama; EFFICACY OF AFLIBERCEPT IN JAPANESE PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY INSENSITIVE TO RANIBIZUMAB TREATMENT. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3836.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To report the short-term efficacy of aflibercept in Japanese patients who were diagnosed with polypoidal choroidal vasculopathy (PCV) and had poor responses to ranibizumab.

Methods: Eleven patients were identified at the National Tokyo Medical Center who had been diagnosed with PCV on fluorescein/indocyanine green angiography and had no marked response to or developed tachyphylaxis in response to ranibizumab. The average number (± standard deviation) of intravitreal ranibizumab (IVR) injections was 12.9 ± 10.9. Subsequently, all patients received intravitreal aflibercept (IVA) injections. The treatment protocol included three IVA injections monthly. To assess the drug efficacy, the following three clinical parameters were evaluated: best-corrected logarithm of the minimum angle of resolution visual acuity (VA), central retinal thickness (CRT), and fluid absorption/reduction subretinally or in the sub-retinal pigment epithelial (RPE) space. Spectral-domain optical coherence tomography was used to assess the second and third parameters. The baseline data were compared to those obtained at the first visit 1 month after the first IVA injection and the last visit 1 month after the third injection.

Results: The average VA/CRT at baseline, the first follow-up visit, and the last follow-up visit were 0.45 ± 0.36/277.8 ± 66.7 microns, 0.44 ± 0.33 (p=0.7150)/210 ± 69.2 microns (p=0.012), and 0.38 ± 0.36 (p=0.2489)/241 ± 66.5 microns (p=0.109), respectively. Absorption/reduction of subretinal or sub-RPE fluid occurred in all 11 patients.

Conclusions: The efficacy of aflibercept has been documented predominantly on architectural changes in Japanese patients with PCV. A specific effect could be suggested for PCV, which presumably has a different pathophysiology from exudative age-related macular degeneration in Caucasian patients.

Keywords: 412 age-related macular degeneration • 453 choroid: neovascularization  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×